Search Results - "OLEFSKY, J"

Refine Results
  1. 1

    Omega-3 fatty acids reduce obesity-induced tumor progression independent of GPR120 in a mouse model of postmenopausal breast cancer by Chung, H, Lee, Y S, Mayoral, R, Oh, D Y, Siu, J T, Webster, N J, Sears, D D, Olefsky, J M, Ellies, L G

    Published in Oncogene (01-07-2015)
    “…Obesity and inflammation are both risk factors for a variety of cancers, including breast cancer in postmenopausal women. Intake of omega-3 polyunsaturated…”
    Get full text
    Journal Article
  2. 2

    Thiazolidinediones in the treatment of insulin resistance and type II diabetes by Saltiel, A. R., Olefsky, J. M.

    Published in Diabetes (New York, N.Y.) (01-12-1996)
    “…Thiazolidinediones in the treatment of insulin resistance and type II diabetes. A R Saltiel and J M Olefsky Department of Signal Transduction, Parke-Davis…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes by Hsiao, A., Worrall, D. S., Olefsky, J. M., Subramaniam, S.

    Published in Bioinformatics (22-11-2004)
    “…Motivation: Microarrays are becoming an increasingly common tool for observing changes in gene expression over a large cross section of the genome. This…”
    Get full text
    Journal Article
  5. 5

    PPARγ and the Treatment of Insulin Resistance by Olefsky, Jerrold M, Saltiel, Alan R

    Published in Trends in Endocrinology & Metabolism (01-11-2000)
    “…Numerous studies across several population groups have indicated that insulin resistance plays a central role in the development of type 2 diabetes mellitus…”
    Get full text
    Book Review Journal Article
  6. 6
  7. 7

    Thiazolidinediones in the treatment of insulin resistance and type II diabetes by SALTIEL, A. R, OLEFSKY, J. M

    Published in Diabetes (New York, N.Y.) (01-12-1996)
    “…Insulin resistance, characterized by reduced responsiveness to normal circulating concentrations of insulin, is a common feature of almost all patients with…”
    Get full text
    Journal Article
  8. 8

    VAMPIRE microarray suite: a web-based platform for the interpretation of gene expression data by Hsiao, Albert, Ideker, Trey, Olefsky, Jerrold M., Subramaniam, Shankar

    Published in Nucleic acids research (01-07-2005)
    “…Microarrays are invaluable high-throughput tools used to snapshot the gene expression profiles of cells and tissues. Among the most basic and fundamental…”
    Get full text
    Journal Article
  9. 9

    Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle by He, W, Barak, Y, Hevener, A, Olson, P, Liao, D, Le, J, Nelson, M, Ong, E, Olefsky, J.M, Evans, R.M

    “…Syndrome X, typified by obesity, insulin resistance (IR), dyslipidemia, and other metabolic abnormalities, is responsive to antidiabetic thiazolidinediones…”
    Get full text
    Journal Article
  10. 10

    Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects by Kruszynska, Y T, Yu, J G, Olefsky, J M, Sobel, B E

    Published in Diabetes (New York, N.Y.) (01-04-2000)
    “…Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Y…”
    Get full text
    Journal Article
  11. 11

    Metabolic effects of Troglitazone monotherapy in type 2 diabetes mellitus : A randomized, double-blind, placebo-controlled trial by MAGGS, D. G, BUCHANAN, T. A, POLONSKY, K. S, SILVER, D, VALIQUETT, T. R, SHULMAN, G. I, BURANT, C. F, CLINE, G, GUMBINER, B, HSUEH, W. A, INZUCCHI, S, KELLEY, D, NOLAN, J, OLEFSKY, J. M

    Published in Annals of internal medicine (01-02-1998)
    “…Troglitazone is a new insulin-sensitizing agent used to treat type 2 diabetes mellitus. The mechanism by which troglitazone exerts its effect on systemic…”
    Get full text
    Journal Article
  12. 12

    A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1 by Haruta, T, Uno, T, Kawahara, J, Takano, A, Egawa, K, Sharma, P M, Olefsky, J M, Kobayashi, M

    Published in Molecular endocrinology (Baltimore, Md.) (01-06-2000)
    “…Insulin receptor substrate-1 (IRS-1) is a major substrate of the insulin receptor and acts as a docking protein for Src homology 2 domain containing signaling…”
    Get full text
    Journal Article
  13. 13

    Effects of Peroxisome Proliferator-Activated Receptor δ on Placentation, Adiposity, and Colorectal Cancer by Barak, Yaacov, Liao, Debbie, He, Weimin, Ong, Estelita S., Nelson, Michael C., Olefsky, Jerrold M., Boland, Richard, Evans, Ronald M.

    “…Targeting of the nuclear prostaglandin receptor peroxisome proliferator-activated receptor δ (PPARδ) by homologous recombination results in placental defects…”
    Get full text
    Journal Article
  14. 14

    A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients by YU, J. G, KRUSZYNSKA, Y. T, MULFORD, M. I, OLEFSKY, J. M

    Published in Diabetes (New York, N.Y.) (01-12-1999)
    “…A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. J G Yu , Y T Kruszynska…”
    Get full text
    Journal Article
  15. 15

    Protein tyrosine phosphatase 1B interacts with the activated insulin receptor by Seely, B. L., Staubs, P. A., Reichart, D. R., Berhanu, P., Milarski, K. L., Saltiel, A. R., Kusari, J., Olefsky, J. M.

    Published in Diabetes (New York, N.Y.) (01-10-1996)
    “…Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. B L Seely , P A Staubs , D R Reichart , P Berhanu , K L Milarski , A R Saltiel ,…”
    Get full text
    Journal Article
  16. 16

    Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency by Miles, P D, Barak, Y, He, W, Evans, R M, Olefsky, J M

    Published in The Journal of clinical investigation (01-02-2000)
    “…The thiazolidinedione class of insulin-sensitizing, antidiabetic drugs interacts with peroxisome proliferator-activated receptor gamma (PPAR-gamma). To gain…”
    Get full text
    Journal Article
  17. 17

    Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects by SUTER, S. L, NOLAN, J. J, WALLACE, P, GUMBINER, B, OLEFSKY, J. M

    Published in Diabetes care (01-02-1992)
    “…Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. S L Suter , J J Nolan , P Wallace , B Gumbiner and J M Olefsky Department of…”
    Get full text
    Journal Article
  18. 18
  19. 19

    TNF-α-induced insulin resistance in vivo and its prevention by troglitazone by MILES, P. D. G, ROMEO, O. M, HIGO, K, COHEN, A, RAFAAT, K, OLEFSKY, J. M

    Published in Diabetes (New York, N.Y.) (01-11-1997)
    “…Tumor necrosis factor (TNF)-alpha may play a role in the insulin resistance of obesity and NIDDM. Troglitazone is a new orally active hypoglycemic agent that…”
    Get full text
    Journal Article
  20. 20

    TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone by Miles, P. D., Romeo, O. M., Higo, K., Cohen, A., Rafaat, K., Olefsky, J. M.

    Published in Diabetes (New York, N.Y.) (01-11-1997)
    “…TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone. P D Miles , O M Romeo , K Higo , A Cohen , K Rafaat and J M Olefsky Department…”
    Get full text
    Journal Article